Best Life Sciences Platforms and Tools Companies in New York City, United States
The 50 best Life Sciences Platforms and Tools companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kallyope.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Web popularity | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kallyope Discovering novel therapeutics for neurological and metabolic diseases | $479M | 39 mo ago | 84 84 → 64 (-24%) | Charles Zuker Co-Founder | — | Series D | 134 patents NK3 receptor modulators for treating neurological and metabolic disorders | — |
| 2 | BioArray Solutions Beadchip for biomolecular analysis | $57M | 229 mo ago | 28 | Jeffrey Binder CEO | — | Acquired | 288 patents Multiplexed nucleic‑acid detection and typing using micro‑particle array platforms | — |
| 3 | Anterios Research-based biopharmaceutical company discovering and delivering innovative medicines | $27M | 159 mo ago | 8 | Robert Nicolosi Co-Founder | — | Acquired | 152 patents Topical and transdermal nanoparticle drug delivery formulations for peptides and cosmetics | — |
| 4 | Remedy Pharmaceuticals Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and… | $23M | 116 mo ago | 6 | — | — | Acquired | — | — |
| 5 | TARA Biosystems AI-driven platform transforming drug discovery and development for better patient outcomes | $21M | 73 mo ago | 11 | Kacey Bouchard Co-Founder | — | Acquired | — | — |
| 6 | Gencove Cloud platform for personal genomics | $16M | 57 mo ago | 31 | — | Top 50M | Series A | 2 patents Integrated low‑pass whole‑genome and targeted DNA sequencing for comprehensive genomic analysis | — |
| 7 | Promosome Provides technical platforms for enhancing both yield and quality in the production of bio-therapeutic and… | $14M | 186 mo ago | 14 | — | — | Deadpooled | — | — |
| 8 | Coridea Medical device incubator creating innovative solutions for cardiology, pulmonary, and renal patients 7Funding top 38%Moat top 45%Global bottom 43%Patents bottom 30% All 6 signals ▾Fundingtop 38% Moattop 45% Globalbottom 43% Patentsbottom 30% Marketbottom 21% Innovationbottom 21% Funding: Raised $12.5M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 7/100 | $12M | 10 mo ago | 9 | — | — | Series A | 5 patents Medical devices for cardiopulmonary therapy and steerable spine implant delivery systems | — |
| 9 | Bridge Medicines Accelerating drug discovery from academic research to human proof of concept | $10M | 68 mo ago | 4 | — | — | Series A | 18 patents Small‑molecule inhibitors of ENL/AF9 YEATS domains and FLT3 kinase for leukemia therapy | — |
| 10 | Yesse Technologies Developer of nanochip based olfactory system | $10M | 66 mo ago | 8 | — | — | Seed | — | — |
| 11 | NovaSterilis Supercritical CO2 sterilization technology and services for medical and life sciences | $9M | 17 mo ago | 9 | David Burns president and ceo | Top 50M | Funding Raised | 14 patents Supercritical CO₂ sterilization and processing of medical, food, and biomaterial products | — |
| 12 | Harmonic Discovery Developer of kinase inhibitor drugs for oncology | $8M | 47 mo ago | 7 | Rayees Rahman Co-Founder & CEO | — | Seed | — | — |
| 13 | AminoChain A blockchain-based platform for tokenizing and incentivizing stem cell donations | $7M | 23 mo ago | — | Caspar Barnes Founder & CEO | Top 50M | Seed | 4 patents Blockchain tokenization of biospecimens and AI-driven consent management for biobanking | 1 launch · 2 partnerships |
| 14 | PIN Pharma US-based, preclinical-stage biopharma, developing a broad-base immunomodulatory cancer therapy | $7M | — | 1 | — | — | Series A | — | — |
| 15 | 3D Bio Corporation 3D Bio-printed living tissues | $5M | 88 mo ago | 17 | — | — | Series A | — | — |
| 16 | CytoDel Developing recombinant botulinum toxin derivatives for targeted intraneuronal therapeutic delivery | $5M | 43 mo ago | 6 | — | — | Seed | 2 patents Engineered botulinum neurotoxins for safer therapeutic and cosmetic applications | — |
| 17 | Morgan and Mendel Genomics Provider of technology platform based on a combination of flow cytometry and Western blot | $4M | 94 mo ago | 7 | — | — | Funding Raised | — | — |
| 18 | Gene Link Supplier of custom oligonucleotides, siRNA, fluorescent probes, genetic tools, and reagents | $3M | 159 mo ago | — | Ali Javed Founder & Director | Top 10M | Public | — | — |
| 19 | Balto Therapeutics Rapid oral dissolving formulations for patients with difficulty swallowing | $3M | 106 mo ago | 2 | Thomas Fernandez Co-Founder | — | Deadpooled | — | — |
| 20 | RUMI Scientific Provider of proprietary human stem cell platform for screening genetic diseases | $2M | 27 mo ago | 6 | Ali Brivanlou Co-Founder | — | Funding Raised | — | — |
| 21 | TEZCAT Laboratories Developing therapies for cancer treatment | $2M | 14 mo ago | — | Andrew Hauser Co-Founder & COO | — | Funding Raised | — | — |
| 22 | Spheryx Particle characterization solutions using Total Holographic Characterization for diverse applications | $2M | 39 mo ago | 13 | Laura Philips Founder & CEO | — | Seed | 10 patents Advanced holographic imaging for particle characterization and cell viability assays | 2 launchs |
| 23 | SensoDx Programmable bio-nano-chip for protein, drug, oligonucleotide, cell counting and cytology assays | $2M | 82 mo ago | — | John T. McDevitt Founder & Chief Science Officer | — | Deadpooled | — | — |
| 24 | CyteQuest Provider of in vitro electroporation based assay for single-cell analysis | $1M | 49 mo ago | 3 | Tom Corso Co-Founder | — | Seed | 19 patents High-throughput microfluidic electroporation devices for cellular gene delivery | — |
| 25 | FitBiomics Provider of next-generation sequencing of microbiome of elite athletes | $816K | 148 mo ago | 15 | Aleksandar Kostic Co-Founder | Top 5M | Funding Raised | 12 patents Probiotic nutritional supplements enhancing human health and athletic performance | — |
| 26 | A2A Pharmaceuticals AI-driven pharmaceutical company developing novel drug alternatives for life-threatening diseases | $250K | 118 mo ago | 4 | Edward Painter Founder | — | Seed | — | — |
| 27 | Seraph Robotics 3 D printers | $225K | 147 mo ago | — | Adam Perry Tow Co-Founder & CEO | — | Deadpooled | — | — |
| 28 | Base5 Biosciences Domain name potentially related to biotechnology or pharmaceutical research | $193K | 138 mo ago | — | Kate Meyer Co-Founder | — | Deadpooled | — | — |
| 29 | Qrons Developer of 3D printable smart material scaffolds | $125K | 70 mo ago | 2 | — | — | Public | 3 patents Polymeric hydrogel platforms for drug delivery and neuronal regeneration therapies. | — |
Top 12 Life Sciences Platforms and Tools companies in New York City
#1
Series A · New York City, New York · founded 2003 · 9 employees$12.5Mraised▾
Medical device incubator creating innovative solutions for cardiology, pulmonary, and renal patients. This incubator specializes in medical device innovation, focusing on unmet needs in cardiac, pulmonary, and renal care. They invent and translate healthcare solutions into impactful devices, offering hope to patients with limited treatment options. With a proven track record, they launch companies focused on these critical areas, driving advancements in medical technology. Their expertise lies in medical device incubation, venture capital, clinical research, ideation, intellectual property, and start-ups, fostering a pipeline of groundbreaking medical solutions. They aim to expand their portfolio and launch new ventures regularly, contributing to the evolution of healthcare.
- Sep 2025Grant (prize money)$2.7M
- Apr 2025Grant (prize money)$2.2M
- Jun 2024Grant (prize money)$274.8K
- May 2023Grant (prize money)$2M
#2
Funding Raised · New York City, New York · founded 2000 · 9 employees$9.5Mraised▾
Supercritical CO2 sterilization technology and services for medical and life sciences. The company provides environmentally friendly sterilization solutions, offering an alternative to EO with broader compatibility, including biologics. They cater to industries like medical devices, regenerative medicine, combination products, biotherapeutics, APIs, life sciences R&D tools, and additive manufacturing. Offerings include sterilization equipment, sterilization services, and supercritical CO2 technology. They focus on advancing product safety and patient outcomes through novel supercritical CO2 solutions, providing a safer, gentler, and more effective terminal sterilization process. They serve tissue banking, regenerative medicine, and medical device markets with equipment, additives, and processes, performing contract research on applications of scCO2 across a broad range of materials.
- Mar 2025Grant (prize money)$2M
- Jul 2022Grant (prize money)$2M
- Jul 2015Grant (prize money)$1.2M
- Feb 2015Grant (prize money)$147.3K
#3
Series D · New York City, New York · founded 2014 · 84 employees$479Mraised▾
Discovering novel therapeutics for neurological and metabolic diseases. The company focuses on addressing significant health challenges by developing effective and well-tolerated agents. Utilizing the Klarity Platform, scientists investigate medicines targeting metabolism, including type 2 diabetes and obesity, and neurological disorders like migraine and pain. The company pursues innovative approaches to medicine discovery, integrating technologies for differentiated therapeutic development. With a team of scientists and drug developers, the company fosters a culture of innovation and collaboration to advance human health. The company operates in the pharmaceutical and biotechnology sectors, focusing on research and development to create solutions for unmet medical needs. The company's work has a direct social impact by aiming to improve the lives of patients and families affected by these diseases.
- May 2023Grant (prize money)$8.2M
- Feb 2022Series D$236M
- Mar 2020Series C$112M
- Dec 2018Series B$21M
#4
Funding Raised · New York City, New York · founded 2018$2.2Mraised▾
TEZCAT is developing therapies for cancer treatment. It is focusing on colorectal cancer and its technology block cancer processes such as nutrient scavenging via macropinocytosis and YAPL signaling.
- May 2025Grant (prize money)$2.2M
#5
Seed · New York City, New York · founded 2022$7.1Mraised▾
A blockchain-based platform for tokenizing and incentivizing stem cell donations. It offers a decentralized bio-sample marketplace that connects biobanks and clinical sites with bio-pharma companies. The company focuses on tokenizing stem cells and creating incentives for donors to participate.
- Aug 2024Seed$7.1M
#6
Funding Raised · New York City, New York · founded 2015 · 6 employees$2.2Mraised▾
Provider of proprietary human stem cell platform for screening genetic diseases. The company have fused stem cell biology and physics to develop a micro patterning technology. The company uses its micropatterning technology to grow human embryonic stem cells (hESCs). The company has developed an isogenic line for the Huntington’s Disease mutation.
- May 2024Grant (prize money)$1M
- May 2023Grant (prize money)$300K
- Mar 2020Grant (prize money)$400K
- Sep 2019Grant (prize money)$299.9K
#7
Series A · New York City, New York · founded 2016 · 31 employees$16.2Mraised▾
Gencove, formerly seeq.io, is a personal genomics service. The company's focus is centered around its app-based data reporting system. The client purchases a kit that is used to transport saliva to the company's labs, where it undergoes ultra-low coverage whole genome sequencing. The data is analyzed and shared with the client through the app, which allows the client to explore ancestry and information about the oral microbiome with friends easily. The client can also download the raw sequencing data for analysis at their end. The company also gives the clients, the possibility to participate in population genetics studies, in addition to designing and executing population genomics research programs for clients.
- Oct 2021Series A$10M
- Apr 2021Series A$1.8M
- May 2019Grant (prize money)$212.2K
- Feb 2019Series A$3M
#8
Seed · New York City, New York · founded 2012 · 6 employees$5Mraised▾
Developing recombinant botulinum toxin derivatives for targeted intraneuronal therapeutic delivery. This biopharmaceutical company focuses on creating a new class of antibody fusion proteins using its recombinant botulinum toxin platform. This platform enables the specific delivery of therapeutic proteins to previously inaccessible targets within the neuronal cytoplasm. The company's programs include biodefense applications and treatments for nervous system disorders and chronic pain. They are also developing a biobetter botulinum toxin with an improved safety margin for treating large muscles and muscle groups. The company utilizes recombinant protein engineering to produce atoxic derivatives that retain the intraneuronal trafficking properties of native botulinum toxin, with a controllable safety profile customized to specific indications. This technology has potential applications in both the peripheral and central nervous system, addressing conditions with high unmet medical need.
- Jan 2023Grant (prize money)$295.4K
- Mar 2022Grant (prize money)$414.9K
- Jan 2018Seed$3.9M
- Apr 2017Seed$150K
#9
Acquired · New York City, New York · founded 2001 · 28 employees$56.8Mraised▾
Bioarray solutions focuses on developing bead-based assays for nucleic acid and protein analysis.It has also developed products for genetic diagnostics and infectious disease agent profiling, and, FDA clearance for an autoantibody profiling ("ENA") BeadChip™ assay on its Array Imaging System. Its BeadChip(TM) system deploys planar arrays of proprietary encoded microparticles to perform rapid and reliable molecular analysis of nucleic acids and proteins.The company was acquired by Immucor in March, 2008.
- 2007Series E$25M
- 2006Series D$20M
- Jun 2005Series B$1.3M
- Jan 2005Series B$10.5M
#10
Seed · New York City, New York · founded 2021 · 7 employees$8.1Mraised▾
Developer of kinase inhibitor drugs for oncology. The company's platform integrates biological screening and medicinal chemistry with computational chemistry to predict clinical resistance mutations and optimize the design of small molecule therapeutics to maintain binding to their key targets and avoid harmful off-target interactions, enabling medical practitioners to treat cancer more effectively.
- Sep 2022Seed$8M
- 2021Seed$125K
#11
Acquired · New York City, New York · founded 2014 · 11 employees$21.2Mraised▾
AI-driven platform transforming drug discovery and development for better patient outcomes. The company harnesses high-quality patient data and powerful Artificial Intelligence-driven technology to accelerate the creation of life-changing medicines. Through its Opal Computational Platform, it combines machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. It is a new kind of company, made possible by advances in technology and patient data and dedicated to advancing their combined power. The company is focused on innovating drug discovery and development in pursuit of better health outcomes for patients everywhere.
- Jun 2020Series A$10M
- Oct 2017Series A$9M
- Dec 2015Seed$2.2M
#12
Seed · New York City, New York · founded 2014 · 13 employees$1.8Mraised▾
Particle characterization solutions using Total Holographic Characterization for diverse applications. The company offers innovative analytical services and products for particle analysis at the sub-visible level. Their Total Holographic Characterization technology provides a new approach to understanding suspensions across various industries, including pharmaceuticals, semiconductors, water quality, consumer products, and academic research. They provide user-friendly interface and compliant software suite. The company's technology enables improved product development, monitoring, and control, leading to better products, reduced waste, and increased efficiency. They cater to both B2B and B2C markets, offering solutions for quality assurance and process optimization. Their offerings include analytical services, software, and specialized techniques like Holographic Video Microscopy.
- Apr 2023Seed$675K
- Dec 2018Seed$525K
- Sep 2016Grant (prize money)$1.3M
- Sep 2016Grant (prize money)$748K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat6
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.